Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Ad26.ZEBOV and MVA-BN-Filo prime-boost Ebola vaccine regimens in healthy adults, children, and adults with HIV infection
PACTR202002606736841Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Sep 2015
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Phase 2 trial of zabdeno and Mvabea, sponsored by Johnson & Johnson. Started Sep 2015; status: completed.
02
Drugs
zabdenoMvabea
Beyond the preview
Go deeper on PACTR202002606736841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202002606736841.